MyoKardia steps closer to the launch of a groundbreaking heart trial after finding its low-dose starting point
MyoKardia $MYOK is one step closer to launching a pivotal trial for its genetically targeted lead heart drug.
In the second part of their two-step Phase II trial, the South San Francisco-based biotech says it landed positive data for a slate of endpoints with their low-dose approach to obstructive hypertrophic cardiomyopathy. That’s encouraging them to drop off the top and bottom doses from the full scale up and focus on the 5 mg, 10 mg and 15 mg steps in the range.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.